Association Between β-Blockers and Outcome of Coronary Artery Bypass Grafting: Before and After 1 Year

BackgroundWe evaluated the long-term outcomes of coronary artery bypass grafting (CABG) according to β-blocker therapy using landmark analysis. Although β-blockers have been shown improve for ischemic heart disease, effects and optimal treatment duration use after CABG remain unknown.MethodsFrom January 2001 December 2014, 5382 patients were stratified into 2 groups at discharge (β-blocker group: 3677 [68.3%], no 1705 [31.7%]).ResultsThe primary outcome was all-cause death during 48 months follow-up. Using propensity score-matched analysis, associated with 48-month follow-up (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.41-0.95; P = .03). The analysis demonstrated that effect on particularly significant within first 12 (HR, 0.37; CI, 0.19-0.80; .01) but not 0.92; 0.56-1.53; .77).ConclusionsThe benefits postdischarge may be limited 1 year CABG, further studies are required confirm this finding. We unknown. From [31.7%]). .77).